Hodgkin Lymphoma

Brentuximab vedotin compared with standard therapy for patients with advanced-stage Hodgkin’s Lymphoma: a cost-effectiveness analysis

Patients with advanced Hodgkin’s Lymphoma (HL) have been with the combination of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and have largely positive outcomes.

Leads

Dean Regier

More Info about Brentuximab vedotin compared with standard therapy for patients with advanced-stage Hodgkin’s Lymphoma: a cost-effectiveness analysis

Deciphering the genome biology of relapsed lymphoid cancers to improve patient management

The PACER lab leads the health economics activities of this multi-year research project in collaboration with researchers from the Genome Sciences Centre and the Centre for Lymphoid Cancer.

Leads

Dean Regier

More Info about Deciphering the genome biology of relapsed lymphoid cancers to improve patient management

BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.

Donate Today

Brentuximab vedotin compared with standard therapy for patients with advanced-stage Hodgkin’s Lymphoma: a cost-effectiveness analysis

Deciphering the genome biology of relapsed lymphoid cancers to improve patient management

BC Cancer Research

Office of Research Administration

Cancer Control Research

Genome Sciences Centre

Terry Fox Laboratory

Molecular Oncology

Integrative Oncology

Experimental Therapeutics

Lymphoid Cancer Research

Clinical Research

Deeley Research Centre